This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Recent health updates include Texas experiencing a lull in measles cases, Omada’s successful Nasdaq debut, no bird flu ...

Novo Nordisk A/S NVO shares lost 2.7% on Friday after a surprising announcement regarding changes to its executive leadership and board of directors. Per the press release, Lars Fruergaard ...

Novo Nordisk’s type 2 diabetes drug Ozempic has expanded its label to include chronic kidney disease. The new FDA approval comes as makers of GLP-1 drugs work to expand the uses of these products.

Novo Nordisk announced Friday that it would part ways with its longtime CEO, who steered the company into an unprecedented boom time for weight-loss drugs. The Ozempic maker’s chief executive ...

The runaway success of GLP-1 drugs made Novo Nordisk, a Danish drugmaker ... They help fight diabetes, obesity, heart disease and possibly may have uses for other ailments. Steven Goldstein ...

As a pioneer in diabetes care, Novo Nordisk has been in the business ... Dicerna acquisition in 2021 also brings rights to kidney disease drug candidate nedosiran (approved as Rivfloza) and ...

When investing on a budget, buying fractional shares of top companies is one option. Two great options right now are Novo ...